GenMark Diagnostics

GenMark Diagnostics, Inc. is a molecular diagnostics company dedicated to the development and commercialization of its patented electronic sensing (eSensor) detection technology. The company's proprietary electrochemical technology enables the rapid, accurate, and highly sensitive detection of 72 different biomarkers within a single sample. The company’s XT-8 system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). GenMark supports various molecular diagnostic tests through software packages, user-friendly workstations, and standalone disposable test cartridges. Within 30 minutes of receiving extracted and amplified nucleic acid samples, the XT-8 system delivers clear and accurate results. The XT-8 system supports 24 independently operated test cartridges, offering high convenience and flexibility in workflow for its target customers, which include hospitals and reference laboratories. The company has developed four diagnostic tests using the XT-8 system and aims to expand its test portfolio at a rate of two to four new tests per year. The company’s cystic fibrosis genotyping test and thrombophilia risk assessment test have received FDA clearance. The former detects potential risks of cystic fibrosis and assesses the oral metabolism of the anticoagulant warfarin, while the latter evaluates the risk of thrombosis.